Identification

Name
Brompheniramine
Accession Number
DB00835  (APRD00832)
Type
Small Molecule
Groups
Approved
Description

Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. [PubChem]

Structure
Thumb
Synonyms
  • [3-(4-Bromo-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine
  • 1-(P-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
  • 2-(P-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine
  • 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine
  • 3-(P-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
  • BPN
  • Bromfeniramina
  • Brompheniramin
  • Bromphéniramine
  • Brompheniraminum
External IDs
AHR 1843 / D 721
Product Ingredients
IngredientUNIICASInChI Key
Brompheniramine maleateIXA7C9ZN03980-71-2SRGKFVAASLQVBO-BTJKTKAUSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimegan Inj 10mg/mlLiquid10 mgIntramuscular; SubcutaneousDexo Sa Labs Pharms1988-12-311997-05-30Canada
Dimetane Elixir 2mg/5mlElixir2 mgOralWhitehall Robins Inc.1993-12-311997-08-07Canada
Dimetane Tab 4mgTablet4 mgOralWhitehall Robins Inc.1957-12-312000-07-26Canada
J-tan PdLiquid1 mg/mLOralJay Mac Pharmaceuticals2007-05-292016-10-13Us
International/Other Brands
Bromfed (Wockhardt USA, LLC) / Bromfenex (Ethex Corporation) / Dimetane (Wyeth) / Lodrane (ECR Pharmaceuticals)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Cold and Allergy ChildrensBrompheniramine maleate (1 mg/5mL) + Phenylephrine hydrochloride (2.5 mg/5mL)LiquidOral7 Eleven2014-08-05Not applicableUs
Alahist DMBrompheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralPoly Pharmaceuticals2007-12-27Not applicableUs
Altidec ABrompheniramine maleate (2 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)LiquidOralAlternative Pharmacal Corporation2015-03-012017-01-25Us
Altipres-BBrompheniramine maleate (4 mg/5mL) + Dextromethorphan hydrobromide (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL)LiquidOralAlternative Pharmacal Corporation2012-11-01Not applicableUs
AP-Hist DMBrompheniramine maleate (4 mg/mL) + Dextromethorphan hydrobromide (15 mg/mL) + Phenylephrine hydrochloride (7.5 mg/mL)LiquidOralAllegis Pharmaceuticals, LLC2013-04-15Not applicableUs
Assured Childrens Cold and CoughBrompheniramine maleate (1 mg/5mL) + Dextromethorphan hydrobromide (5 mg/5mL) + Phenylephrine hydrochloride (2.5 mg/5mL)LiquidOralBio Pharm, Inc.2011-11-01Not applicableUs
Atuss DaBrompheniramine maleate (2 mg/5mL) + Chlophedianol hydrochloride (12.5 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralCarwin Associates, Inc2016-10-25Not applicableUs
Atuss DaBrompheniramine maleate (2 mg/5mL) + Chlophedianol hydrochloride (12.5 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralAber Pharmaceuticals, Llc2016-02-082017-02-14Us
Auro Tap Childrens Cold and AllergyBrompheniramine maleate (1 mg/5mL) + Phenylephrine hydrochloride (2.5 mg/5mL)SolutionOralAurohealth LLC2015-06-042015-12-29Us
Auromine Childrens Cold and AllergyBrompheniramine maleate (1 mg/5mL) + Phenylephrine hydrochloride (2.5 mg/5mL)SolutionOralAurohealth LLC2015-12-15Not applicableUs
Categories
UNII
H57G17P2FN
CAS number
86-22-6
Weight
Average: 319.239
Monoisotopic: 318.073161265
Chemical Formula
C16H19BrN2
InChI Key
ZDIGNSYAACHWNL-UHFFFAOYSA-N
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
IUPAC Name
[3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.

Structured Indications
Pharmacodynamics

Brompheniramine is an antihistaminergic medication of the propylamine class. It is a first-generation antihistamine. In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Brompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of action

Brompheniramine works by acting as an antagonist of the H1 histamine receptors. It also functions as a moderately effective anticholingeric agent, likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine. Its effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Antihistamines are well absorbed from the gastrointestinal tract after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic (cytochrome P-450 system), some renal.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat: LD50 = 318 mg/kg. Signs of overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Brompheniramine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Brompheniramine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Brompheniramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Brompheniramine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brompheniramine.Experimental
AbirateroneThe serum concentration of Brompheniramine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brompheniramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brompheniramine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Brompheniramine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brompheniramine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brompheniramine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brompheniramine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Brompheniramine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brompheniramine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Brompheniramine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brompheniramine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brompheniramine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Brompheniramine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Brompheniramine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Brompheniramine.Approved, Illicit
AprepitantThe serum concentration of Brompheniramine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.Approved, Investigational
ArmodafinilThe metabolism of Brompheniramine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Brompheniramine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Brompheniramine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brompheniramine.Approved
AtazanavirThe metabolism of Brompheniramine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Brompheniramine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Brompheniramine.Investigational, Vet Approved
AzelastineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Brompheniramine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Brompheniramine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Brompheniramine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brompheniramine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Brompheniramine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brompheniramine.Approved
Benzylpenicilloyl PolylysineBrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Brompheniramine.Approved
BetaxololThe metabolism of Brompheniramine can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Brompheniramine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Brompheniramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Brompheniramine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Brompheniramine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Brompheniramine.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Brompheniramine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brompheniramine.Approved, Investigational
BuprenorphineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Brompheniramine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brompheniramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brompheniramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Brompheniramine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Brompheniramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Brompheniramine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Brompheniramine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brompheniramine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Brompheniramine.Investigational
CapecitabineThe metabolism of Brompheniramine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Brompheniramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brompheniramine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brompheniramine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brompheniramine.Approved
CelecoxibThe metabolism of Brompheniramine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Brompheniramine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brompheniramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brompheniramine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Brompheniramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brompheniramine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Brompheniramine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brompheniramine.Approved
ChloroquineThe metabolism of Brompheniramine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Brompheniramine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Brompheniramine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brompheniramine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brompheniramine.Approved
CholecalciferolThe metabolism of Brompheniramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Brompheniramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Brompheniramine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brompheniramine.Approved, Vet Approved
CitalopramThe metabolism of Brompheniramine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Brompheniramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Brompheniramine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Brompheniramine.Approved
ClobazamThe metabolism of Brompheniramine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Brompheniramine.Investigational
ClomipramineThe metabolism of Brompheniramine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brompheniramine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Brompheniramine.Experimental
ClopidogrelThe metabolism of Brompheniramine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brompheniramine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Brompheniramine.Experimental
ClotrimazoleThe metabolism of Brompheniramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Brompheniramine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Brompheniramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Brompheniramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brompheniramine.Approved, Illicit
ConivaptanThe serum concentration of Brompheniramine can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Brompheniramine can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Brompheniramine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.Approved
CyclosporineThe metabolism of Brompheniramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brompheniramine.Approved
Cyproterone acetateThe serum concentration of Brompheniramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brompheniramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Brompheniramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Brompheniramine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Brompheniramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Brompheniramine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Brompheniramine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Brompheniramine.Approved
DesipramineThe metabolism of Brompheniramine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Brompheniramine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brompheniramine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Brompheniramine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brompheniramine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brompheniramine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brompheniramine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brompheniramine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Brompheniramine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Brompheniramine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brompheniramine.Approved, Illicit
DihydroergotamineThe metabolism of Brompheniramine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brompheniramine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brompheniramine.Experimental, Illicit
DiltiazemThe metabolism of Brompheniramine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Brompheniramine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brompheniramine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Brompheniramine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Brompheniramine.Vet Approved
DosulepinThe metabolism of Brompheniramine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxepin.Approved
DoxorubicinThe metabolism of Brompheniramine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Brompheniramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brompheniramine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Illicit
DronedaroneThe metabolism of Brompheniramine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brompheniramine.Experimental, Illicit
DuloxetineThe metabolism of Brompheniramine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brompheniramine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Brompheniramine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brompheniramine.Approved, Investigational
EliglustatThe metabolism of Brompheniramine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Brompheniramine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Brompheniramine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Brompheniramine.Approved, Investigational
EnzalutamideThe serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Brompheniramine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Brompheniramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Brompheniramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brompheniramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brompheniramine.Approved
EthanolBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brompheniramine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brompheniramine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Brompheniramine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brompheniramine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brompheniramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Brompheniramine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Brompheniramine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Brompheniramine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Brompheniramine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brompheniramine.Illicit, Vet Approved
EtravirineThe metabolism of Brompheniramine can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Felbamate.Approved
FelodipineThe metabolism of Brompheniramine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brompheniramine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brompheniramine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Brompheniramine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Brompheniramine.Experimental
FluconazoleThe metabolism of Brompheniramine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brompheniramine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brompheniramine.Approved, Illicit
FluorouracilThe metabolism of Brompheniramine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Brompheniramine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brompheniramine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brompheniramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brompheniramine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brompheniramine.Approved
FluvastatinThe metabolism of Brompheniramine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Brompheniramine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Brompheniramine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Brompheniramine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Brompheniramine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brompheniramine.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Brompheniramine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brompheniramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brompheniramine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Brompheniramine can be decreased when combined with Gemfibrozil.Approved
GepefrineGepefrine may decrease the sedative activities of Brompheniramine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Brompheniramine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Brompheniramine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Brompheniramine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Brompheniramine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Brompheniramine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brompheniramine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brompheniramine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.Approved, Investigational
HydrocodoneBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Brompheniramine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
IdelalisibThe serum concentration of Brompheniramine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Iloperidone.Approved
ImatinibThe metabolism of Brompheniramine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Brompheniramine can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Brompheniramine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Brompheniramine.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Brompheniramine.Approved
IrbesartanThe metabolism of Brompheniramine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Brompheniramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Brompheniramine.Approved, Vet Approved
IsoniazidThe metabolism of Brompheniramine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Brompheniramine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Brompheniramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Brompheniramine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brompheniramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brompheniramine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brompheniramine.Approved, Investigational
KetoconazoleThe metabolism of Brompheniramine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brompheniramine.Approved, Investigational
LapatinibThe metabolism of Brompheniramine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Brompheniramine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Brompheniramine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brompheniramine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brompheniramine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brompheniramine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Brompheniramine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Brompheniramine.Approved
LobeglitazoneThe metabolism of Brompheniramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brompheniramine.Illicit
LopinavirThe metabolism of Brompheniramine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Brompheniramine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brompheniramine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brompheniramine.Approved
LorcaserinThe metabolism of Brompheniramine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Brompheniramine.Approved
LosartanThe metabolism of Brompheniramine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Brompheniramine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brompheniramine.Approved
LuliconazoleThe serum concentration of Brompheniramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Brompheniramine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Brompheniramine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Vet Approved
ManidipineThe metabolism of Brompheniramine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Brompheniramine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Brompheniramine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Brompheniramine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Brompheniramine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Brompheniramine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Brompheniramine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Brompheniramine.Investigational
MephentermineMephentermine may decrease the sedative activities of Brompheniramine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brompheniramine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Brompheniramine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brompheniramine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.Approved
MethadoneThe metabolism of Brompheniramine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brompheniramine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Brompheniramine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brompheniramine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brompheniramine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Brompheniramine.Approved
MethotrimeprazineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brompheniramine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Brompheniramine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brompheniramine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brompheniramine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Brompheniramine.Approved, Investigational
MetyrosineBrompheniramine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Brompheniramine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Brompheniramine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Brompheniramine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Investigational
MirabegronThe metabolism of Brompheniramine can be decreased when combined with Mirabegron.Approved
MirtazapineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Brompheniramine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Brompheniramine.Experimental, Illicit
MoclobemideThe metabolism of Brompheniramine can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Brompheniramine can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Brompheniramine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Brompheniramine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brompheniramine.Approved
NefazodoneThe metabolism of Brompheniramine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Brompheniramine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Brompheniramine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Brompheniramine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Brompheniramine can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Brompheniramine can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Brompheniramine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brompheniramine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brompheniramine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Brompheniramine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brompheniramine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brompheniramine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brompheniramine.Approved, Investigational
OlaparibThe metabolism of Brompheniramine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brompheniramine.Approved
OmeprazoleThe metabolism of Brompheniramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brompheniramine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brompheniramine.Approved, Illicit
OrphenadrineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Brompheniramine.Investigational
OsimertinibThe serum concentration of Brompheniramine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brompheniramine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Brompheniramine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brompheniramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brompheniramine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brompheniramine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Brompheniramine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brompheniramine.Approved
PanobinostatThe serum concentration of Brompheniramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Brompheniramine can be decreased when combined with Pantoprazole.Approved
ParaldehydeBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Brompheniramine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Brompheniramine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.Approved, Vet Approved
PentobarbitalThe metabolism of Brompheniramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Brompheniramine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Brompheniramine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brompheniramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brompheniramine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Brompheniramine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Brompheniramine.Experimental
PhenobarbitalThe metabolism of Brompheniramine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Brompheniramine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Brompheniramine.Approved
PhenterminePhentermine may decrease the sedative activities of Brompheniramine.Approved, Illicit
PhenytoinThe metabolism of Brompheniramine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Brompheniramine.Approved
PioglitazoneThe metabolism of Brompheniramine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brompheniramine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Brompheniramine.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Brompheniramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleBrompheniramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brompheniramine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brompheniramine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brompheniramine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Brompheniramine.Approved
PrimidoneThe metabolism of Brompheniramine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Brompheniramine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.Approved, Vet Approved
PromazineThe metabolism of Brompheniramine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Brompheniramine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brompheniramine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Brompheniramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Brompheniramine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Brompheniramine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Brompheniramine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Brompheniramine.Approved
PyrimethamineThe metabolism of Brompheniramine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Brompheniramine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.Approved
QuinidineThe metabolism of Brompheniramine can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Brompheniramine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Brompheniramine.Experimental
RabeprazoleThe metabolism of Brompheniramine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Brompheniramine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Brompheniramine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brompheniramine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brompheniramine.Approved, Investigational
RifabutinThe metabolism of Brompheniramine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Brompheniramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Brompheniramine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Brompheniramine.Investigational
RitobegronRitobegron may decrease the sedative activities of Brompheniramine.Investigational
RitonavirThe metabolism of Brompheniramine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Brompheniramine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Brompheniramine.Vet Approved
RopiniroleBrompheniramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine.Approved
RosiglitazoneThe metabolism of Brompheniramine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineBrompheniramine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brompheniramine.Approved
SaquinavirThe metabolism of Brompheniramine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.Approved
SecobarbitalThe metabolism of Brompheniramine can be increased when combined with Secobarbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Brompheniramine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brompheniramine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Brompheniramine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brompheniramine.Approved, Vet Approved
SildenafilThe metabolism of Brompheniramine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Brompheniramine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Brompheniramine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
SorafenibThe metabolism of Brompheniramine can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Brompheniramine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Brompheniramine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.Approved, Investigational
SulfadiazineThe metabolism of Brompheniramine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Brompheniramine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Brompheniramine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brompheniramine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Brompheniramine.Experimental
SuvorexantBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Brompheniramine can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Brompheniramine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Brompheniramine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Brompheniramine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brompheniramine.Approved
TerbinafineThe metabolism of Brompheniramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Brompheniramine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brompheniramine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Brompheniramine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brompheniramine.Investigational
ThalidomideBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brompheniramine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Brompheniramine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Brompheniramine.Approved, Withdrawn
ThiotepaThe metabolism of Brompheniramine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brompheniramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Brompheniramine.Approved, Investigational
TicagrelorThe metabolism of Brompheniramine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Brompheniramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Brompheniramine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Brompheniramine.Experimental
TipranavirThe metabolism of Brompheniramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.Approved
TocilizumabThe serum concentration of Brompheniramine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Brompheniramine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brompheniramine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Brompheniramine.Approved
TopiroxostatThe metabolism of Brompheniramine can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Brompheniramine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brompheniramine.Experimental
TranylcypromineThe metabolism of Brompheniramine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Brompheniramine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brompheniramine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Brompheniramine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Brompheniramine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brompheniramine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Brompheniramine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brompheniramine.Approved, Vet Approved
TrimethoprimThe metabolism of Brompheniramine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brompheniramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brompheniramine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Brompheniramine.Approved, Investigational
ValsartanThe metabolism of Brompheniramine can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Brompheniramine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Brompheniramine.Experimental
VerapamilThe metabolism of Brompheniramine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Brompheniramine.Experimental
VoriconazoleThe metabolism of Brompheniramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brompheniramine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Brompheniramine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Brompheniramine.Vet Approved
ZafirlukastThe metabolism of Brompheniramine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brompheniramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Brompheniramine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Brompheniramine.Vet Approved
ZolpidemBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Brompheniramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Brompheniramine.Approved, Investigational
ZucapsaicinThe metabolism of Brompheniramine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brompheniramine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Sperber, N., Papa, D. and Schwenk, E.; US. Patent 2,567,245; September 11, 1951; assigned to Schering Corporation. Sperber, N., Papa, D. and Schwenk, E.; U.S. Patent 2,676,964: April 27,1954; assigned to Schering Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB01941
KEGG Drug
D00663
KEGG Compound
C06857
PubChem Compound
6834
PubChem Substance
46508137
ChemSpider
6573
BindingDB
50017666
ChEBI
3183
ChEMBL
CHEMBL811
Therapeutic Targets Database
DAP001066
PharmGKB
PA448675
Drugs.com
Drugs.com Drug Page
Wikipedia
Brompheniramine
ATC Codes
R06AB51 — Brompheniramine, combinationsR06AB01 — Brompheniramine
AHFS Codes
  • 04:04.20 — Propylamine Derivatives
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentNasal Congestion and Inflammations / Rhinitis1
3WithdrawnTreatmentCoughing / Inflammatory Reaction / Rhinitis1
Not AvailableCompletedTreatmentAllergic Reactions1

Pharmacoeconomics

Manufacturers
  • Alpharma us pharmaceuticals division
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Usl pharma inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Wyeth consumer healthcare
  • Barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Newtron pharmaceuticals inc
  • Nexgen pharma inc
  • Par pharmaceutical inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Vitarine pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral
SolutionOral
Tablet, chewableOral
LiquidOral
Kit
LiquidIntramuscular; Subcutaneous10 mg
ElixirOral2 mg
TabletOral4 mg
Tablet, extended releaseOral
CapsuleOral
Solution / dropsOral
LiquidOral1 mg/mL
ElixirOral
TabletOral
SyrupOral
Prices
Unit descriptionCostUnit
Brompheniramine maleate powder9.83USD g
Brovex ct 12 mg tablet chew1.58USD tablet
Brompheniramine 12 mg tablet chew1.42USD tablet
Bromfenex-pd capsule sa0.56USD capsule
Bromfed-dm cough syrup0.21USD ml
Brom-pseud-dm syrup0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)149.5 °C at 5.00E-01 mm HgPhysProp
water solubilityFreely soluble (maleate salt)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.63ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.67 m3·mol-1ChemAxon
Polarizability32.08 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9648
Blood Brain Barrier+0.9576
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6242
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.93
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.5898
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8398
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.9351
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0758 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9121
hERG inhibition (predictor II)Inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0002-5490000000-9c3b804de0b552198b85
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-014i-4954000000-f0a4889ab8cd0d5dcacc
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-00di-0090000000-02a74d4d4927d8e443aa
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-014i-0920000000-ad3d20cb0f1b7362fbc3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Bromobenzenes / Aralkylamines / Aryl bromides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organobromides / Hydrocarbon derivatives
Substituents
Pheniramine / Bromobenzene / Halobenzene / Aralkylamine / Aryl bromide / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organobromine compound, pyridines (CHEBI:3183)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053]
  2. Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615]
  3. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410]
  4. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  5. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33